OBJECTIVES: The reference pricing system is used for setting drug prices in Turkey since 2006. There are 5 reference countries following; Spain, Italy, Germany, France and Greece. Except those countries, manufactured or imported countries may be used as reference countries. Reference prices are reviewed time by time and may be subject to certain alterations, but evaluation of box prices may be different if evaluation made based on milligram. The aim of this study is to evaluate differences of average milligram sales prices of some generic medicines between Turkey and European countries.  METHODS: Comparison of miligram based prices analysis between European countries  done by Intelligent Health System(IHS) was used. The analysis of IHS included Germany, France, United Kingdom(UK), Spain and Italy(EU5).  Comparison was done with taken row data of analysis EU5 and Turkey average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine molecules. RESULTS: It has been reported that compared 10 molecules highest average miligram based prices of Esomeprazole(0,043 €), Levofloxacin(0,058 €)  and  Clopidogrel(0,0083 €) molecules belong to Turkey, Lamotrigine(0,01 €) belongs to Germany. The highest average miligram based prices of other 6 molecules belong to UK with following; Ceftriaxone(0,0196 €), Fentanyl(0,186 €), Letrozole(1,24 €), Metformine(0,00013 €), Venlafaxine(0,0074 €), Olanzapine(0,261 €). CONCLUSIONS: It has known that because of UK used free pricing mechanism on drugs, prices of drugs are higher than other compared countries. This sitiuation established on the anaylsis. But despite of Turkish Government policy decisions; it is important indiciation that 3 drugs represents highest prices out 10 drugs. Reference pricing system applied based on box price. Better control mechanism may achievable if miligram based pricing apply in Turkey. On the other hand because of the study only consist retail sales prices the evaluation should be done from point of reimbursement prices on future studies.